Eubacterium hallii (E. hallii) has been identified as a candidate for next generation probiotics (NGPs) with exciting potential for the prevention and treatment of such dysbiosis-associated diseases. Creative Biolabs offers well-established and innovative One-Stop-Shop live biotherapeutic products (LBP) solutions. We are flexible to meet the unique needs of LBP client projects.
E. hallii is an anaerobic, Gram-positive, catalase-negative bacterium belonging to the Lachnospiraceae family of the phylum Firmicutes that is present in both murine and human faeces. These bacteria are represented by a rigid cell wall. They are non-motile. E. hallii is a butyrate-producing species. Interestingly, unlike other intestinal isolates such as Roseburia and Faecalibacterium that produce butyric acid from monosaccharides, E. hallii also can produce butyrate from lactate and acetate in low pH environments, such as the proximal small intestine. It is considered as the common gut microbe that contributes to intestinal propionate formation. E. hallii has been widely used in the pharmaceutical, food and feed industries. For example, it has been used to treat complications associated with insulin resistance, such as dyslipidemia, Cushing’s syndrome, type 1 diabetes mellitus, endocrine diseases, etc.
Fig.1 Graphical summary of E. hallii interactions in gut epithelium responsible for maintaining host health. (Almeida, 2020)
An altered intestinal microbiota composition is associated with insulin resistance and type 2 diabetes mellitus. Scientists previously identified increased intestinal levels of Eubacterium hallii in metabolic syndrome subjects who received a faecal transplant from a lean donor. To further assess the effects of E. hallii on insulin sensitivity, we orally treated obese and diabetic db/db mice with alive E. hallii and glycerol or heat inactive E. hallii as control. Experimental results showed that oral active E. hallii improved insulin sensitivity and significantly increased energy expenditure in db/db mice with severe insulin resistance. It was found that treatment with active E. hallii increased fecal butyric acid concentration and changed bile acid metabolism. These findings suggested that E. hallii administration potentially altered the function of the intestinal microbiome and that microbial metabolites may contribute to the improved metabolic phenotype, which potentially contributes to the beneficial effects of E. hallii treatment on insulin sensitivity in obese and diabetic db/db mice.
Fig.2 E. hallii treatment improves insulin sensitivity and energy expenditure. (Udayappan, 2016)
We supply a variety of E. hallii strains of different preservation numbers as below. If you need other strains, please contact us.
E. hallii is a promising candidate as keystones species so far identified that hopefully will have a great impact on the fight against metabolic and inflammatory dysbiosis-derived diseases. Creative Biolabs can apply our considerable experience with LBP development to develop the necessary analytics specific to your project. If you are interested in our E. hallii related services or products, please feel free to contact us for more.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.